Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Safe MRI with cardiac implants

You may also be interested in...



New Products In Brief

Boston Scientific’s next-generation Promus Element Plus drug-eluting stent; Biotronik’s first-of-its-kind MRI-safe ICD; BSD Medical’s BSD-2000 cervical cancer treatment. More new products.

FDA Should Use “Bully Pulpit” To Lower MRI Accident Rate, Workshop Goers Say

While overseeing MRI operators is outside FDA's purview, participants at an FDA workshop agreed that the agency should use its “bully pulpit” to at least encourage safer use of magnetic resonance imaging equipment.

FDA Should Use “Bully Pulpit” To Lower MRI Accident Rate, Workshop Goers Say

While overseeing MRI operators is outside FDA's purview, participants at an FDA workshop agreed that the agency should use its “bully pulpit” to at least encourage safer use of magnetic resonance imaging equipment.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel